Does Medicare Cover GLP-1 Medications? (2026)
Coverage rules, copays, prior auth requirements, and appeal options for Medicare members seeking Wegovy, Ozempic, Zepbound, or Mounjaro.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Coverage by Medication[8]
| Medication | Medicare Coverage |
|---|---|
| Wegovy (semaglutide) | Medicare Part D excludes drugs prescribed for weight loss under the statutory exclusion at SSA 1860D-2(e)(2)(A). Per CMS HPMS memo issued March 20, 2024, Wegovy may be covered under Part D when prescribed for the FDA-approved cardiovascular-risk-reduction indication (reducing risk of MACE in adults with established CVD who are obese or overweight, supported by the SELECT trial). Plan-level coverage and PA criteria vary. |
| Ozempic (semaglutide) | Covered under Medicare Part D for type 2 diabetes diagnosis. |
| Zepbound (tirzepatide) | Not covered under Medicare Part D for weight loss (statutory exclusion). Zepbound has a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity; Part D coverage for the OSA indication is plan-dependent. |
| Mounjaro (tirzepatide) | Covered under Medicare Part D for type 2 diabetes diagnosis. |
| Typical copay (when covered) | $30-$100 / month |
If You're Denied by Medicare
If Medicare denies coverage for Wegovy or Zepbound, you still have affordable options. Compounded semaglutide and tirzepatide are dispensed by licensed 503A pharmacies[7] and cost $149-$299/month — a fraction of brand-name pricing. Brand-name GLP-1 medications are generally an HSA/FSA-eligible medical expense with a prescription[5], and many plan administrators also accept compounded GLP-1s with a Letter of Medical Necessity. The providers below ship to all 50 states and offer same-week prescriptions.
Medicare statutory note: Medicare Part D is statutorily prohibited from covering “agents when used for anorexia, weight loss, or weight gain” under § 1860D-2(e)(2)(A) of the Social Security Act. This is why Wegovy and Zepbound are not covered for obesity indications, even when they are otherwise on a plan's formulary for diabetes or cardiovascular indications[3].
Before going cash-pay, file a formal appeal with Medicare. Many denials are overturned with a Letter of Medical Necessity from your prescriber documenting BMI, comorbidities, and prior failed weight-loss attempts.
Top Compounded Alternatives
Editorial score · methodology
Editorial score · methodology
LaSara Medical Group
Best for: patients in southern California who want hybrid in-person + telehealth access, or patients seeking a one-stop hormone-and-GLP-1 clinic and willing to confirm pricing + state coverage during the free consultation
Editorial score · methodology
Get StartedRead full LaSara Medical Group review →LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Editorial score · methodology
myRocky
Best for: US patients in the 42 supported states who specifically want brand-name FDA-approved GLP-1 receptor agonists without insurance involvement AND are also managing additional conditions covered by myRocky's multi-product platform (sexual health, hair loss, mental health) so the $99/mo program fee amortizes across multiple medications. NOT recommended for patients sensitive to total monthly cost — compounded providers ($99-$199/mo) and direct manufacturer programs (NovoCare, LillyDirect) offer better economics.
Editorial score · methodology
Roen Rx
Best for: patients with insurance seeking brand-name GLP-1 access with compounded fallback
Editorial score · methodology
RxPros
Best for: price-sensitive patients comfortable with annual prepayment to lock in the lowest compounded GLP-1 monthly rate in the market
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Medicare Coverage Updates
Get notified when Medicare GLP-1 coverage rules change.
Sources & methodology — as of May 2026
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.Weight Loss Rankings insurer coverage index (manually curated formulary data)— Weight Loss Rankings.